Spotlight: BIOWeek:Boston 2018

BIOWeek:Boston 2018 The Complete Guide to the Week of the BIO International Convention June 3-8, 2018 Big3Bio Releases The First Version of BIOWeek:Boston 2018, The Complete Guide to the Week of #BIO2018       SAN FRANCISCO, CA–(May 25, 2018)–Big3Bio, the leading aggregator service for the top biotech hubs in the US—Boston, San Francisco Bay [...]

May 27th, 2018|

May Financial Focus: Boston Area a Hot-Bed for Biopharma Startups

By Marie Daghlian VC funding for Boston area biotech companies is on fire and its momentum shows no signs of slowing up. Boston area biotech and health-related companies raised $1.58 billion in 32 deals in the first quarter of 2018. That compares favorably with the $1.59 billion raised in Q4 2017 in 42 deals, and [...]

May 14th, 2018|

Spotlight Q&A with Rob Neville, CEO, Savara Pharmaceuticals

About Savara Pharmaceuticals: Savara Inc. (NASDAQ: SVRA) is an orphan lung disease company. Savara's pipeline comprises a number of late stage therapeutics each targeting difficult to treat lung diseases. Rob Neville CEO, Savara Pharmaceuticals For people not familiar with Savara, can you provide a brief overview and focus? Neville: Savara was founded in [...]

April 2nd, 2018|

Spotlight: Virginia Capezio from TriNet Talks About How Biotech Companies Can Tackle the Tough HR Considerations in 2018

Virginia Capezio is a senior human resources consultant with TriNet, a company that provides full-service HR solutions to small and midsize businesses. Here, Virginia talks about the changing landscape of the biotech workplace, how broader trends may be affecting the environment and the big HR issues biotech companies should be thinking about in the new [...]

January 8th, 2018|

Advancing Drug Development Forum – Making the Impossible Possible

Time: 08:30-19:30 Registration fees: Academic Attendee:  $195, General Attendee:  $395 Register here: Click here to register for this event   Forum description: Register for this ground-breaking inaugural event to explore new solutions, promising technology breakthroughs and how industry can introduce and incorporate improved approaches in drug development. The program, proudly sponsored by Juniper Pharma Services, [...]

November 10th, 2017|

From Candidate Selection to Market: Navigating Challenges in Biotechnology

  Not every drug development program follows a similar path to regulatory approval. Don’t miss out on this Charles River workshop which will bring together industry professionals to provide guidance on key components and considerations for designing and optimizing your drug development program. The workshop will include interactive sessions to discuss how to attract investors, [...]

October 10th, 2017|

Spotlight: Fostering a Culture of Innovation to Drive Growth

Develop an Innovative Culture As companies look to generate new growth, many are concerned that their culture may be inhibiting them from achieving their goals. While many people believe a stronger culture that supports innovation will lead to growth, most lack clarity about what the true impact improving culture has on innovation and what types [...]

September 27th, 2017|

Charles River 23rd Annual Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development Symposium

The Charles River 23rd Annual Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development symposium will be held September 11-13, 2017 at Cape Rey Resort, Carlsbad, CA. This three-day symposium with five sessions has a jam-packed agenda with case study presentations from industry leaders from Bluebird, Janssen, Pfizer and Amgen in the nonclinical development of biotherapeutics. Don’t miss out on [...]

July 24th, 2017|

Advancing Rare Disease Drug Discovery: Navigating the Path to an IND

Symposium Overview: Therapies to treat rare and undiagnosed diseases are in high demand in a favorable regulatory environment. Thus, it is critically important to optimize the discovery and development of such therapies by creating – and following – the most efficient path to an investigational new drug (IND) filing. How do we do just that? [...]

April 5th, 2017|